Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Inhibitory Effect of Human Anti-CA I Autoantibodies and Development of Monoclonal Antibody mAb 2B8 Targeting Carbonic Anhydrase I

P. Chalova, B. Jankovicova, V. Dvorakova, E. Zelinkova, Z. Bilkova, M. Slovakova, L. Korecka, P. Muller, M. Danchenko, L. Minichova, J. Lakota, L. Skultety

. 2024 ; 2024 (-) : 9981131. [pub] 20241230

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc25010545

Spontaneous tumor regression is a recognized phenomenon across various cancer types. Recent research emphasizes the alterations in autoantibodies against carbonic anhydrase I (CA I) (anti-CA I) levels as potential prognostic markers for various malignancies. Particularly, autoantibodies targeting CA I and II appear to induce cellular damage by inhibiting their respective protein's catalytic functions. Our study illuminates the profound impact of anti-CA I autoantibodies from patient serum on the esterase activity of human CA I, exhibiting inhibitory effects akin to the acetazolamide inhibitor. Concurrently, our newly synthesized mouse monoclonal IgG antibody, mAb 2B8, against human CA I showcased a potent inhibitory action. An in-depth exploration into mAb 2B8's binding dynamics with its target enzyme was undertaken. Leveraging epitope extraction and phage display library techniques, we identified the amino acid sequence DFWTYP (positions 191-196 of CA I) as crucial for mAb 2B8's interaction. In 3-D structural analysis, this sequence is spatially adjacent to a previously identified epitope (DFWTYP) that interacts with patient-derived autoantibodies. Critically, mAb 2B8 demonstrated an ability to infiltrate eukaryotic cells, engaging specifically with its intracytoplasmic target. This positions mAb 2B8 as a promising model for future studies aimed at tumor cell eradication.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25010545
003      
CZ-PrNML
005      
20250429134909.0
007      
ta
008      
250415e20241230xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1155/mi/9981131 $2 doi
035    __
$a (PubMed)39764425
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Chalova, Petra $u Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia $u Department of Pharmaceutical Analysis and Nuclear Pharmacy, Faculty of Pharmacy, Comenius University, Bratislava, Slovakia
245    10
$a Inhibitory Effect of Human Anti-CA I Autoantibodies and Development of Monoclonal Antibody mAb 2B8 Targeting Carbonic Anhydrase I / $c P. Chalova, B. Jankovicova, V. Dvorakova, E. Zelinkova, Z. Bilkova, M. Slovakova, L. Korecka, P. Muller, M. Danchenko, L. Minichova, J. Lakota, L. Skultety
520    9_
$a Spontaneous tumor regression is a recognized phenomenon across various cancer types. Recent research emphasizes the alterations in autoantibodies against carbonic anhydrase I (CA I) (anti-CA I) levels as potential prognostic markers for various malignancies. Particularly, autoantibodies targeting CA I and II appear to induce cellular damage by inhibiting their respective protein's catalytic functions. Our study illuminates the profound impact of anti-CA I autoantibodies from patient serum on the esterase activity of human CA I, exhibiting inhibitory effects akin to the acetazolamide inhibitor. Concurrently, our newly synthesized mouse monoclonal IgG antibody, mAb 2B8, against human CA I showcased a potent inhibitory action. An in-depth exploration into mAb 2B8's binding dynamics with its target enzyme was undertaken. Leveraging epitope extraction and phage display library techniques, we identified the amino acid sequence DFWTYP (positions 191-196 of CA I) as crucial for mAb 2B8's interaction. In 3-D structural analysis, this sequence is spatially adjacent to a previously identified epitope (DFWTYP) that interacts with patient-derived autoantibodies. Critically, mAb 2B8 demonstrated an ability to infiltrate eukaryotic cells, engaging specifically with its intracytoplasmic target. This positions mAb 2B8 as a promising model for future studies aimed at tumor cell eradication.
650    _2
$a lidé $7 D006801
650    12
$a autoprotilátky $x imunologie $x metabolismus $7 D001323
650    12
$a karboanhydrasa I $x metabolismus $x antagonisté a inhibitory $7 D024401
650    12
$a monoklonální protilátky $x imunologie $7 D000911
650    _2
$a zvířata $7 D000818
650    _2
$a myši $7 D051379
650    _2
$a epitopy $x imunologie $x chemie $7 D000939
655    _2
$a časopisecké články $7 D016428
700    1_
$a Jankovicova, Barbora $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic
700    1_
$a Dvorakova, Veronika $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic
700    1_
$a Zelinkova, Eliska $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic $1 https://orcid.org/0000000241063062
700    1_
$a Bilkova, Zuzana $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic $1 https://orcid.org/0000000245166659 $7 mzk2004221796
700    1_
$a Slovakova, Marcela $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic $1 https://orcid.org/0000000249750983 $7 xx0105097
700    1_
$a Korecka, Lucie $u Department of Biological and Biochemical Sciences, Faculty of Chemical Technology, University of Pardubice, Pardubice, Czech Republic $1 https://orcid.org/0000000205682915 $7 jo2012709734
700    1_
$a Muller, Petr $u Regional Centre for Applied Molecular Oncology, Masaryk Memorial Cancer Institute, Brno, Czech Republic $1 https://orcid.org/0000000284044494 $7 xx0036920
700    1_
$a Danchenko, Maksym $u Institute of Chemistry, Slovak Academy of Sciences, Bratislava, Slovakia $1 https://orcid.org/0000000236760728
700    1_
$a Minichova, Lenka $u Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia $1 https://orcid.org/0000000271711729
700    1_
$a Lakota, Jan $u Institute of Normal and Pathological Physiology, Centre of Experimental Medicine, Slovak Academy of Sciences, Bratislava, Slovakia $1 https://orcid.org/000000027088488X
700    1_
$a Skultety, Ludovit $u Biomedical Research Center, Slovak Academy of Sciences, Bratislava, Slovakia $u Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic $1 https://orcid.org/0000000298306459
773    0_
$w MED00006378 $t Mediators of inflammation $x 1466-1861 $g Roč. 2024 (20241230), s. 9981131
856    41
$u https://pubmed.ncbi.nlm.nih.gov/39764425 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250415 $b ABA008
991    __
$a 20250429134905 $b ABA008
999    __
$a ok $b bmc $g 2311737 $s 1247626
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 2024 $c - $d 9981131 $e 20241230 $i 1466-1861 $m Mediators of inflammation $n Mediators Inflamm $x MED00006378
LZP    __
$a Pubmed-20250415

Najít záznam

Citační ukazatele

Možnosti archivace